CTi Biopharma Corp Stock Research

Market Summary

USD9.04-0.01

Delayedas of 01 Jun 2023, 01:00 pm

-0.11%

CTIC Alerts

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)
Losses in recent quarter

CTIC Stock Price

CTIC RSI Chart

CTIC Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-17.24

Price/Sales (Trailing)

15.75

Price/Free Cashflow

-14.5

CTIC Price/Sales (Trailing)

CTIC Profitability

Operating Margin

93.49%

Return on Equity

529.06%

Return on Assets

-73.85%

Free Cashflow Yield

-6.9%

CTIC Fundamentals

CTIC Revenue

Revenue (TTM)

75.8M

Revenue Y/Y

950.81%

Revenue Q/Q

14.39%

CTIC Earnings

Earnings (TTM)

-69.2M

Earnings Y/Y

63.9%

Earnings Q/Q

23.12%

Price Action

52 Week Range

4.019.05

(Low)(High)

Last 7 days

0.6%

Last 30 days

85.1%

Last 90 days

66.7%

Trailing 12 Months

66.7%

CTIC Financial Health

Current Ratio

1.23

CTIC Investor Care

Shares Dilution (1Y)

31.07%

Diluted EPS (TTM)

-0.56

Peers (Alternatives to CTi Biopharma)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	117.9B	26.2B	-7.64%	-12.03%	14.89	4.5	-0.48%	38.34%
GILD	96.0B	27.0B	-5.50%	23.66%	17.2	3.55	-1.56%	23.65%
MRNA	49.0B	15.1B	-4.27%	-12.12%	10.25	3.26	-33.37%	-67.32%
BIIB	42.8B	10.1B	-4.73%	48.21%	13.67	4.24	-6.61%	115.98%
MID-CAP
NBIX	8.7B	1.6B	-13.93%	-4.24%	136.39	5.46	32.38%	-10.36%
DNLI	4.1B	-	17.13%	24.41%	-11.15	38.1	122.90%	-29.67%
BEAM	2.4B	76.7M	3.81%	-9.32%	-7.51	30.96	41.73%	-32.75%
BBIO	2.2B	107.9M	-4.32%	100.88%	-4.54	20.39	54.84%	17.36%
SMALL-CAP
RCUS	1.5B	119.0M	11.39%	8.39%	-5.38	12.62	-69.61%	-584.39%
REPL	1.1B	10.0M	8.51%	30.70%	-6.18	107.56	215.65%	-47.65%
NVAX	694.6M	-	4.27%	-85.45%	-0.6	0.35	72.89%	12.32%
FATE	495.9M	136.9M	-20.60%	-78.14%	-2.11	3.62	116.83%	-0.93%
SGMO	186.8M	241.0M	-25.83%	-69.32%	-1.47	0.78	113.96%	27.87%
VXRT	165.4M	697.0K	50.34%	-66.48%	-1.53	237.34	47.98%	-35.48%
IBIO	8.7M	-	-35.78%	-88.38%	-0.11	3.21	0.51%	-129.47%

Financials for CTi Biopharma

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	40.4%	76.00	54.00	44.00	29.00	9.00
S&GA Expenses	4.6%	89.00	85.00	86.00	78.00	67.00
Costs and Expenses	-3.0%	130	134	134	127	116
Interest Expenses	16.1%	15.00	13.00	11.00	8.00	4.00
Net Income	25.5%	-69.24	-92.99	-112	-120	-117
Net Income Margin	32.8%	-1.72*	-2.56*	-3.18*	-12.83*	-
Free Cahsflow	15.2%	-81.19	-95.70	-100	-98.09	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-10.8%	112	126	123	135	131
Current Assets	-13.0%	86.00	99.00	97.00	107	103
Cash Equivalents	-20.4%	24.00	30.00	32.00	66.00	97.00
Inventory	6.0%	1.00	1.00	1.00	1.00	0.00
Net PPE	NaN%	-	-	-	0.00	-
Liabilities	-4.1%	138	144	140	140	159
Current Liabilities	-15.9%	68.00	81.00	30.00	30.00	99.00
LT Debt, Current	0.3%	48.00	48.00	-	-	48.00
LT Debt, Non Current	0.3%	48.00	48.00	-	-	-
Shareholder's Equity	-44.2%	-25.35	-17.58	-27.92	-	-
Retained Earnings	-1.3%	-2,532	-2,500	-2,500	-2,485	-2,463
Additional Paid-In Capital	0.2%	2,507	2,501	2,485	2,480	2,435
Shares Outstanding	0.9%	132	131	127	114	101

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-1.4%	-82.31	-81.19	-95.70	-100	-98.09
Share Based Compensation	8.0%	11.00	10.00	8.00	7.00	6.00
Cashflow From Investing	20.7%	-58.60	-73.85	-74.39	-54.79	4.00
Cashflow From Financing	-43.2%	68.00	120	107	150	158

Risks for CTIC

What is the probability of a big loss on CTIC?

100%

Probability that CTi Biopharma stock will be more than 20% underwater in next one year

100%

Probability that CTi Biopharma stock will be more than 30% underwater in next one year.

98.5%

Probability that CTi Biopharma stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CTIC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if CTi Biopharma was unfortunately bought at previous high price.

Drawdowns

Returns for CTIC

Cumulative Returns on CTIC

-3.0%

10-Year Cumulative Returns

11.1%

7-Year Cumulative Returns

15.4%

5-Year Cumulative Returns

107.0%

3-Year Cumulative Returns

What are the long-term rolling returns for CTIC?

FIve years rolling returns for CTi Biopharma.

Annualized Returns

Which funds bought or sold CTIC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-8.53	-27,938	49,501	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-25.37	-186,000	203,000	-%
2023-05-18	JPMORGAN CHASE & CO	reduced	-5.17	-2,404,000	4,724,000	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	92.37	875,546	3,418,400	-%
2023-05-16	JANE STREET GROUP, LLC	added	312	904,623	1,385,040	-%
2023-05-15	NORGES BANK	sold off	-100	-2,933,480	-	-%
2023-05-15	Walleye Trading LLC	new	-	111,640	111,640	-%
2023-05-15	J. Goldman & Co LP	added	52.39	248,564	4,076,450	0.16%
2023-05-15	TWO SIGMA SECURITIES, LLC	sold off	-100	-328,218	-	-%
2023-05-15	BOOTHBAY FUND MANAGEMENT, LLC	sold off	-100	-642,763	-	-%

Latest Funds Activity

Are funds buying CTIC calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own CTIC

No. of Funds

CTi Biopharma News

Schedule 13G FIlings of CTi Biopharma

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 13, 2023	stonepine capital management, llc	5.3%	7,018,046	SC 13G
Mar 24, 2023	lynch timothy p	5.3%	6,999,275	SC 13G
Feb 13, 2023	stonepine capital management, llc	3.9%	4,934,100	SC 13G/A
Feb 03, 2023	state street corp	12.61%	16,002,989	SC 13G/A
Feb 03, 2023	blackrock inc.	5.6%	7,060,319	SC 13G
Jan 09, 2023	millennium management llc	3.9%	4,962,769	SC 13G/A
Jul 22, 2022	growth equity opportunities v, llc	-	0	SC 13D/A
Jun 17, 2022	growth equity opportunities v, llc	8.8%	9,613,101	SC 13D/A
Jun 13, 2022	millennium management llc	5.5%	5,942,285	SC 13G
Feb 14, 2022	stonepine capital management, llc	9.99%	9,754,935	SC 13G/A

CTIC Fair Value

Show Fair-Value

Recent SEC filings of CTi Biopharma

View All Filings

Date Filed	Form Type	Document
May 30, 2023	8-K	Current Report
May 30, 2023	DEFA14A	DEFA14A
May 25, 2023	SC 14D9	SC 14D9
May 25, 2023	SC TO-T	SC TO-T
May 15, 2023	10-Q	Quarterly Report
May 10, 2023	8-K	Current Report
May 10, 2023	SC TO-C	SC TO-C
May 10, 2023	SC14D9C	SC14D9C
May 10, 2023	SC14D9C	SC14D9C
Apr 28, 2023	ARS	ARS

Latest Insider Trading transactions for CTIC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-24	Fong James K	acquired	94,890	0.9489	100,000	evp & chief commercial officer
2023-01-24	Craig Adam R	acquired	71,760	0.8411	85,317	president and ceo
2023-01-24	Fong James K	sold	-600,000	6.00	-100,000	evp & chief commercial officer
2023-01-24	Craig Adam R	sold	-511,923	6.00025	-85,317	president and ceo
2023-01-03	Craig Adam R	acquired	71,226	0.8411	84,683	president and ceo
2023-01-03	KIRSKE DAVID	sold	-162,423	6.011	-27,021	evp, chief financial officer
2023-01-03	Craig Adam R	sold	-509,224	6.0133	-84,683	president and ceo
2023-01-03	KIRSKE DAVID	acquired	25,640	0.9489	27,021	evp, chief financial officer
2022-12-30	Craig Adam R	acquired	8,066	5.1085	1,579	president and ceo
2022-12-30	Craig Adam R	sold	-102,648	6.00278	-17,100	president and ceo

About CTi Biopharma

Adam R. Craig

http://www.ctibiopharma.com

120

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

CTIC Income Statement

2023-03-31

CONDENSED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net product sales	$ 24,116	$ 2,295
Operating costs and expenses:
Cost of sales	1,224	278
Research and development	10,211	8,048
Selling, general and administrative	21,913	18,046
Other operating expenses	0	11,023
Total operating costs and expenses	33,348	37,395
Loss from operations	(9,232)	(35,100)
Non-operating expenses:
Interest expense, net	(4,183)	(2,063)
Other non-operating expenses	(7)	(12)
Total non-operating expenses	(4,190)	(2,075)
Net loss	$ (13,422)	$ (37,175)
Basic net loss per common share (in dollars per share)	$ (0.10)	$ (0.37)
Diluted net loss per common share (in dollars per share)	$ (0.10)	$ (0.37)
Shares used in calculation of basic net loss per common share (in shares)	131,566	99,834
Shares used in calculation of diluted net loss per common share (in shares)	131,566	99,834

CTIC Balance Sheet

2023-03-31

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 24,209	$ 30,420
Short-term investments	34,802	49,519
Accounts receivable, net	22,957	15,387
Inventories	777	733
Prepaid expenses and other current assets	3,708	3,337
Total current assets	86,453	99,396
Intangible assets, net	22,705	23,226
Other assets	3,114	3,303
Total assets	112,272	125,925
Current liabilities:
Accounts payable	2,025	2,008
Accrued expenses	16,306	29,402
Current portion of long-term debt	48,084	47,943
Other current liabilities	1,811	1,781
Total current liabilities	68,226	81,134
Royalty financing obligation	68,371	61,134
Other liabilities	1,022	1,234
Total liabilities	137,619	143,502
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.001 par value per share:	132	131
Additional paid-in capital	2,506,861	2,501,234
Accumulated other comprehensive loss	(11)	(35)
Accumulated deficit	(2,532,329)	(2,518,907)
Total stockholders’ deficit	(25,347)	(17,577)
Total liabilities and stockholders’ deficit	112,272	125,925
Series X Preferred Stock
Stockholders’ deficit:
Preferred stock, $0.001 par value per share:	0	0
Series X1 Preferred Stock
Stockholders’ deficit:
Preferred stock, $0.001 par value per share:	$ 0	$ 0